A look to future directions in gene therapy research for monogenic diseases.
The concept of gene therapy has long appealed to biomedical researchers and clinicians because it promised to treat certain diseases at their origins. In the last several years, there have been several trials in which patients have benefited from gene therapy protocols. This progress, however, has revealed important problems, including the problem of insertional oncogenesis. In this review, which focuses on monogenic diseases, we discuss the problem of insertional oncogenesis and identify areas for future research, such as developing more quantitative assays for risk and efficacy, and ways of minimizing the genotoxic effects of gene therapy protocols, which will be important if gene therapy is to fulfill its conceptual promise.
Porteus
Matthew H
MH
matthew.porteus@utsouthwestern.edu
Connelly
Jon P
JP
Pruett
Shondra M
SM
D000818:Animals; D002986:Clinical Trials as Topic; D005544:Forecasting; D005814:Genes, Viral / Q000502:physiology; D030342:Genetic Diseases, Inborn / Q000628:therapy*; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods* / Q000639:trends*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D038101:Insulator Elements / Q000502:physiology; D008954:Models, Biological; D016254:Mutagenesis, Insertional / Q000379:methods; D009369:Neoplasms / Q000453:epidemiology; D011519:Proto-Oncogenes / Q000235:genetics; D012106:Research / Q000639:trends*; D018570:Risk Assessment; D012449:Safety; D013234:Stem Cells / Q000378:metabolism; D019076:Transgenes; D016896:Treatment Outcome